Cardio Diagnostics Holdings Inc Registered Shs ISIN: US14159C2026 Forum: Aktien Thema: Hauptdiskussion

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a strategic agreement to launch Cardio Diagnostics’ PrecisionCHD™ test for the detection and management of coronary heart disease (CHD) in India. This partnership marks Cardio Diagnostics’ first expansion outside the United States and official entry into the Indian market. It also represents a major step toward making Cardio Diagnostics’ advanced technology accessible in India, where cardiovascular disease remains a leading and growing health concern. The prevalence of CHD in India varies by population settings, with a prevalence of up to 7.4% and 13% reported in rural and urban areas, respectively.